Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
18
Active, not recruiting, industry sponsors, Respiratory, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed931
18 trials
Showing 1 to 18, recently updated first.
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05692180 · 94 participants · Start Apr 5, 2023 · Primary completion Dec 23, 2026
Drug: Benralizumab; Placebo · For: Asthma
Sites: Torrance, California; Ocala, Florida; Owensboro, Kentucky · 43 sites in all
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05878769 · 2,000 participants (planned) · Start Jun 28, 2023 · Primary completion Jun 30, 2027
Drug: Astegolimab · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Jasper, Alabama · 480 sites in all
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06238622 · 1,666 participants · Start Sep 26, 2024 · Primary completion Apr 28, 2027
Drug: Nerandomilast · For: Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 375 sites in all
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsPivotal-lookingActive, not recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06052267 · 2,769 participants · Start Aug 30, 2023 · Primary completion Dec 31, 2026
Drug: TEV-56248; Albuterol sulfate · For: Asthma
Sites: Birmingham, Alabama; Dothan, Alabama; Paradise Valley, Arizona · 391 sites in all
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT05757102 · 138 participants (planned) · Start Apr 24, 2023 · Primary completion Jan 26, 2027
Drug: FF/UMEC/VI; FF/VI · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Paradise Valley, Arizona · 67 sites in all
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04175600 · 138 participants · Start Jan 16, 2020 · Primary completion Oct 11, 2024
Drug: Selexipag; Placebo and 3 more · For: Hypertension, Pulmonary
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 116 sites in all
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05331183 · 297 participants · Start Nov 23, 2022 · Primary completion Apr 6, 2027
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Innsbruck, Austria; Brussels, Belgium; Edegem, Belgium · 81 sites in all
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Pivotal-lookingActive, not recruiting
Insmed IncorporatedIndustry
NCT05649748 · 91 participants · Start Mar 7, 2023 · Primary completion Dec 31, 2026
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Arterial Hypertension
Sites: Jacksonville, Florida; Tampa, Florida; Chicago, Illinois · 45 sites in all
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05444257 · 822 participants · Start Nov 8, 2022 · Primary completion Oct 30, 2026
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 195 sites in all
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07218029 · 815 participants (planned) · Start May 12, 2021 · Primary completion Dec 7, 2028
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 137 sites in all
- Riociguat in Children With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT02562235 · 24 participants · Start Oct 29, 2015 · Primary completion Mar 7, 2020
Drug: Riociguat (Adempas, BAY63-2521) · For: Hypertension, Pulmonary
Sites: Cali, Colombia; Heidelberg, Germany; Ulm, Germany · 16 sites in all
- A Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06653322 · 401 participants · Start Nov 21, 2024 · Primary completion Sep 2027
Drug: HR-1703; Placebo · For: Asthma With Eosinophilic Phenotype
Sites: Chengdu, China
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06460506 · 50 participants · Start Nov 21, 2024 · Primary completion Sep 30, 2027
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Nedlands, Australia; Parkville, Australia; South Brisbane, Australia · 18 sites in all
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgePivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05422222 · 210 participants (planned) · Start Jun 21, 2022 · Primary completion Jun 30, 2030
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Orange, California; Palo Alto, California; Aurora, Colorado · 38 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06003426 · 1,255 participants · Start Sep 14, 2023 · Primary completion Oct 6, 2026
Drug: BMS-986278; BMS-986278 Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 390 sites in all
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Areteia TherapeuticsIndustry
NCT05748600 · 600 participants (planned) · Start Jan 30, 2023 · Primary completion Sep 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma Attack
Sites: Chandler, Arizona; Peoria, Arizona; Surprise, Arizona · 335 sites in all
- Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of TreprostinilPivotal-lookingActive, not recruiting
Liquidia Technologies, Inc.Industry
NCT03992755 · 92 participants · Start Jul 18, 2019 · Primary completion May 31, 2025
Drug: LIQ861 Inhaled Treprostinil · For: Primary Pulmonary Hypertension
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 25 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.